A carregar...
Can pharmacological receptor tyrosine kinase inhibitors sensitize poor outcome breast tumors to immune-based therapies?
Receptor tyrosine kinases (RTKs) drive breast cancer progression, particularly in human epidermal growth factor receptor 2 and basal tumors, the two worst prognosis subtypes. Tumor cells recruit host stromal components, including immune cells, which strongly influence disease progression. This has b...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3570790/ https://ncbi.nlm.nih.gov/pubmed/23408142 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2013.00023 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|